| 摘要: |
| ［摘要］ 目的 分析安罗替尼联合程序性死亡受体1（PD-1）抑制剂治疗晚期非小细胞肺癌患者的近期临床疗效及对血清血管内皮生长因子（VEGF）、基质金属蛋白酶-2（MMP-2）水平的影响。方法 选择2018年2月至2022年2月成都市第三人民医院收治的110例ⅢB～Ⅳ期非小细胞肺癌患者的临床资料，根据治疗方法不同将其分为联合治疗组（接受安罗替尼联合PD-1抑制剂治疗）和抗PD-1治疗组（接受PD-1抑制剂治疗），每组55例。两组均以21 d为一个治疗周期，每个治疗周期后停药7 d，共治疗3个周期。比较两组治疗前、治疗后1周、治疗后1个月、治疗后3个月的血清VEGF、MMP-2水平，以及疗程结束时的临床疗效。结果 在接受治疗后，两组血清VEGF、MMP-2水平均呈下降趋势（P<0.05），且在治疗后1周、1个月、3个月，联合治疗组水平均较抗PD-1治疗组更低，差异有统计学意义（P<0.05）。联合治疗组的客观缓解率（ORR）、疾病控制率（DCR）均显著高于抗PD-1治疗组，差异有统计学意义（45.45% vs 23.64%，90.91% vs 76.36%；P<0.05）。两组总不良反应发生率比较差异无统计学意义（70.91% vs 78.18%；P>0.05）。结论 安罗替尼联合PD-1抑制剂对晚期非小细胞肺癌患者疗效显著，能降低血清VEGF、MMP-2水平，且安全性较高。 |
| 关键词: 安罗替尼 程序性死亡受体1抑制剂 晚期非小细胞肺癌 血管内皮生长因子 基质金属蛋白酶-2 临床疗效 |
| DOI：10.3969/j.issn.1674-3806.2023.07.15 |
| 分类号:R 734.2 |
| 基金项目:吴阶平医学基金会课题（编号：320.6750.2021-22-27） |
|
| Analysis of the short-term clinical efficacy of anlotinib combined with PD-1 inhibitors in treatment of advanced non-small cell lung cancer patients and its effects on serum VEGF and MMP-2 levels |
|
GAO Hang, YIN Jun, LI Yan-wu
|
|
Department of Respiratory and Critical Care Medicine, the Third People′s Hospital of Chengdu, Sichuan 610031, China
|
| Abstract: |
| ［Abstract］ Objective To analyze the short-term clinical efficacy of anlotinib combined with programmed death-1(PD-1) inhibitors in treatment of advanced non-small cell lung cancer patients and its effects on serum vascular endothelial growth factor(VEGF) and matrix metalloproteinase-2(MMP-2) levels. Methods The clinical data of 110 patients with stage ⅢB-Ⅳ non-small cell lung cancer who were admitted to the Third People′s Hospital of Chengdu from February 2018 to February 2022 were selected and divided into combined treatment group(receiving anlotinib combined with PD-1 inhibitors) and anti-PD-1 treatment group(receiving PD-1 inhibitors) according to different treatment methods, with 55 cases in each group. A treatment cycle of 21 days was performed on both groups, and the drugs were withdrawn 7 days after each treatment cycle, and the treatment lasted for 3 cycles. The serum levels of VEGF and MMP-2 were compared between the two groups before treatment, and 1 week, 1 month and 3 months after treatment, and the clinical efficacy at the end of the course of treatment were compared between the two groups. Results After treatment, the serum levels of VEGF and MMP-2 in the two groups showed a downward trend(P<0.05), and at 1 week, 1 month and 3 months after treatment, the serum levels of VEGF and MMP-2 in the combined treatment group were lower than those in the anti-PD-1 treatment group, and the differences were statistically significant(P<0.05). The objective response rate(ORR) and the disease control rate(DCR) of the combined treatment group were significantly higher than those of the anti-PD-1 treatment group, and the differences were statistically significant(45.45% vs 23.64%, 90.91% vs 76.36%; P<0.05). There was no significant difference in the incidence of total adverse reactions between the two groups(70.91% vs 78.18%; P>0.05). Conclusion Anlotinib combined with PD-1 inhibitors has significant efficacy in treatment of patients with advanced non-small cell lung cancer, and can reduce their serum VEGF and MMP-2 levels, and the safety of the combination of anlotinib and PD-1 inhibitors is relatively high. |
| Key words: Anlotinib Programmed death-1(PD-1) inhibitor Advanced non-small cell lung cancer Vascular endothelial growth factor(VEGF) Matrix metalloproteinase-2(MMP-2) Clinical efficacy |
